U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07327281) titled 'A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects' on Dec. 05, 2025.
Brief Summary: TQF3250 capsule is a biased GLP-1 (glucagon-like peptide-1) receptor agonist developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. By binding to the GLP-1 receptor, it can selectively activate certain signaling pathways of the GLP-1 receptor and reduce activation of other pathways, thereby bringing higher efficacy and lower side effects.
Study Start Date: Dec. 18, 2025
Study Type: INTERVENTIONAL
Condition:
Hyperglycemia
Intervention:
DRUG: TQF3250 placebo
TQF3250 capsule is a biased GLP-1 (glucagon-like peptide-1) r...